Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.
Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.
An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration ...
Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma ...
The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer. The FDA approved osimertinib (Tagrisso) for the treatment of adults with locally ...
Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors. Neoadjuvant immune checkpoint ...
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma ...
A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback